<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732363</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0295124</article-id><article-id pub-id-type="publisher-id">PONE-D-23-23216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Rheumatology</subject><subj-group><subject>Arthritis</subject><subj-group><subject>Rheumatoid Arthritis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Rheumatoid Arthritis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Rheumatoid Arthritis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Rheumatoid Arthritis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>DNA viruses</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Epstein-Barr virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Epstein-Barr virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Epstein-Barr virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Herpesviruses</subject><subj-group><subject>Epstein-Barr virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Clinical Laboratory Sciences</subject><subj-group><subject>Clinical Laboratories</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Artificial Gene Amplification and Extension</subject><subj-group><subject>Polymerase Chain Reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Immunosuppressives</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject><subj-group><subject>Creatinine</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Urea</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Urea</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Extraction techniques</subject><subj-group><subject>DNA extraction</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Frequency and association of Epstein-Barr Virus genotype in rheumatoid arthritis patients of Khyber Pakhtunkhwa, Pakistan</article-title><alt-title alt-title-type="running-head">Epstein-Barr Virus association with rheumatoid arthritis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Munir</surname><given-names>Ayesha</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Suleman</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3164-3036</contrib-id><name><surname>Khan</surname><given-names>Sanaullah</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5463-535X</contrib-id><name><surname>Attaullah</surname><given-names>Sobia</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Munir</surname><given-names>Mehwish</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Saleem</surname><given-names>Aisha</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ali</surname><given-names>Ijaz</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Zoology, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Rheumatology, Lady Reading Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Islamia College (University) Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Abdul Wali Khan University Mardan, Mardan, Khyber Pakhtunkhwa, Pakistan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>CAMB, College of Arts and Sciences, Gulf University for Science and Technology, Hawally, Kuwait</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kato</surname><given-names>Hideo</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Mie University Hospital: Mie Daigaku Igakubu Fuzoku Byoin, JAPAN</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>sanaullahkhan@uop.edu.pk</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>18</volume><issue>12</issue><elocation-id>e0295124</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Munir et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Munir et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0295124.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Rheumatoid arthritis (RA) is an immune-mediated, polyarthritis linked with various genetic and environmental causative agents. Among environmental triggers, Epstein-Barr Virus (EBV) is considered the most potent etiological agent.</p></sec><sec id="sec002"><title>Objective</title><p>This study aimed to investigate the prevalence of EBV and its genotypes in RA patients and to investigate their association with clinical and laboratory parameters of RA.</p></sec><sec id="sec003"><title>Methodology</title><p>This study included blood samples of RA and control healthy individuals (100 each). Blood samples along with clinical and laboratory parameters were collected from patients after consent in the Department of Rheumatology, at Lady Reading Hospital, in Peshawar Pakistan. Blood samples were processed for DNA extraction followed by PCR amplification for EBV detection and genotype discrimination.</p></sec><sec id="sec004"><title>Results</title><p>RA patients were 85 females and 15 males with a mean age of 40.13&#x000b1;14.05 years. EBV Type-1 was detected in 45% of RA and 9% of control cases. The mean disease duration of RA patients was 6.61&#x000b1;6.23 years. Out of 100 diseased patients, 43% were seropositive rheumatoid arthritis (SPRA) and showed a significant correlation with a family history of RA in EBV-positive individuals (P = 0.017). The demographic, clinical, and laboratory parameters of RA patients showed a non-significant association with EBV. Moreover, only a family history and Serum creatinine of RA patients showed a significant association with EBV (P = 0.0001 and P = 0.022 respectively).</p></sec><sec id="sec005"><title>Conclusion</title><p>It is concluded that EBV-1 is prevalent and associated with RA. Further investigation is required for detailed genetic analysis of EBV to determine its possible role in modulating the immune system in RA.</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="9"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder, that predominantly impairs synovial joints affecting 0.5&#x02013;1% of the world&#x02019;s adult population with women being highly prone to be suffered [<xref rid="pone.0295124.ref001" ref-type="bibr">1</xref>]. RA is categorized into two major subsets: seropositive rheumatoid arthritis (SPRA) and seronegative rheumatoid arthritis (SNRA) characterized by the presence or absence of autoantibodies [<xref rid="pone.0295124.ref002" ref-type="bibr">2</xref>]. It is presumed that RA has been linked with several genetic and environmental factors including infectious agents with EBV considered the utmost potent agent in the onset of RA [<xref rid="pone.0295124.ref003" ref-type="bibr">3</xref>]. EBV is a DNA-containing ubiquitous Herpes virus affecting 90% of the world&#x02019;s adult population [<xref rid="pone.0295124.ref004" ref-type="bibr">4</xref>]. It has been classified into two genotypes, type 1 and type 2 based on the EBNA-2 gene which reveals only 54% similarity [<xref rid="pone.0295124.ref005" ref-type="bibr">5</xref>]. EBV latently persists in the body for a lifetime expressing genes involved in mononucleosis and various EBV-associated carcinomas such as Burkitt lymphoma and Hodgkin lymphoma etc [<xref rid="pone.0295124.ref006" ref-type="bibr">6</xref>].</p><p>Several potential mechanisms have been proposed to elucidate the immunomodulatory actions of EBV in the arthritogenicity of RA [<xref rid="pone.0295124.ref007" ref-type="bibr">7</xref>]. Although, it has been suggested that molecular mimicry of EBV antigenic envelop and nuclear amino acid sequence with human leukocyte antigen (HLA) and synovial protein sequence respectively, could be a potential trigger for autoimmunity in a genetically predisposed RA individual [<xref rid="pone.0295124.ref008" ref-type="bibr">8</xref>]. Moreover, EBV- infected RA patients have an aberrant cytotoxic T-cell response and high titer of antibodies to EBV antigens i.e. Epstein-Barr nuclear antigen (EBNA), viral capsid antigen, and early antigen [<xref rid="pone.0295124.ref009" ref-type="bibr">9</xref>].</p><p>Several studies speculated that EBV infection is strongly associated with RA from different parts of the world [<xref rid="pone.0295124.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0295124.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0295124.ref011" ref-type="bibr">11</xref>]. In Pakistan, EBV has been detected in various lymphoma patients from different areas [<xref rid="pone.0295124.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0295124.ref014" ref-type="bibr">14</xref>]. It is reported that RA is prevalent and increasing at a rate of 5.5% per year with a prevalence rate of 12.9&#x02013;26.9% [<xref rid="pone.0295124.ref015" ref-type="bibr">15</xref>]. No data regarding EBV prevalence in RA patients in Pakistan is available to date, therefore this study is designed to find the frequency of EBV and its genotypes in the blood of RA patients and to investigate its possible association with RA clinical and laboratory parameters.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Material and methods</title><sec id="sec008"><title>Study population</title><p>This cross-sectional study comprised of 100 confirmed RA patients and 100 healthy individuals with no RA signs and symptoms. Confirmed RA samples diagnosed by a rheumatologist with established classification criteria of 2010 American College of Rheumatology/European League Against Rheumatism [<xref rid="pone.0295124.ref016" ref-type="bibr">16</xref>] were recruited from the Department of Rheumatology, Lady Reading Hospital Peshawar Khyber Pakhtunkhwa Pakistan between 21 July 2022, and 19 August 2023. The study protocol was approved by the Ethics Committee of Department of Pharmacy, Faculty of Life and Environmental Sciences, University of Peshawar (approval numbers, 520/EC-FLES-UOP/2022), and all patients gave consent for the use of their blood in the present study.</p></sec><sec id="sec009"><title>Data and sample collection</title><p>Clinical and laboratory parameters including C-reactive protein (CRP), white blood cells (WBC), red blood cells (RBC), platelets (PLT), Alanine transaminase (ALT), Alkaline phosphatase (ALP), serum creatinine, urea and type of RA (SPRA or SNRA) were retrieved from the patient&#x02019;s clinical files while primary data including disease duration, family history, and type of immunosuppressive medications, etc. was collected through a predesigned questionnaire after prior consent from each patient. Peripheral blood (~2.5 mL) was collected from the study population under sterile conditions in EDTA blood tubes and was transferred to the Laboratory of Virology and Immunology, Department of Zoology, University of Peshawar Pakistan for EBV detection and genotyping.</p></sec><sec id="sec010"><title>DNA extraction and detection</title><p>The EBV DNA was isolated using GeneJET Genomic DNA Purification Kit (Thermo Scientific&#x02122;, USA) according to the manufacturer&#x02019;s instructions. The DNA was stored at -70&#x000b0;C until further process. The extracted DNA was initially subjected to PCR for amplification using primers PCO3/PCO4 (b-globulin) to confirm the extracted DNA quality (internal control). After that nested PCR was carried out for discrimination of EBV genotypes (type 1 and type 2) using specific primers of EBNA-3C following the protocol of Sharifpour et al. [<xref rid="pone.0295124.ref017" ref-type="bibr">17</xref>]. The first round of PCR was executed in a 25&#x003bc;L mixture, comprising of 10&#x003bc;L of extracted DNA, 2.5&#x003bc;L PCR buffer (10X), 0.5&#x003bc;L dNTPs (10mM), 3&#x003bc;L MgCl<sub>2</sub> (25mM), 6.8&#x003bc;L molecular grade dH<sub>2</sub>O, 0.2&#x003bc;L <italic toggle="yes">Taq</italic> DNA Polymerase (5U/&#x003bc;L) (Fermentas USA) and 1&#x003bc;L (10pmol) of each forward and reverse primer and the reaction was run in a thermal-cycler (Bio-Rad, USA). The condition of nested round was same except the primers and cDNA of first round (4&#x003bc;L) was used. The PCR program of 1<sup>st</sup> and nested round were same as 95&#x000b0;C for 10 min followed by 35 cycle of 94&#x000b0;C for 45 s, 54.5&#x000b0;C for 45 s and 72&#x000b0;C for 45 s with final extension at 72&#x000b0;C for 10 min.</p><p>The nested round PCR product was separated on 1.5% agarose gel and viewed under UV light using a trans-illuminator. The nested PCR product (75bp for EBV type 1 and 168 for EBV type 2) was compared with the DNA ladder (50bp) (<bold><xref rid="pone.0295124.s001" ref-type="supplementary-material">S1 Fig</xref></bold>).</p></sec><sec id="sec011"><title>Statistical analysis</title><p>The obtained results were analyzed using statistical packages for social sciences version 25 (SPSS, Inc, Chicago, IL, USA). Data was analyzed using the Chi-square test for gender, family history and immunosuppressive drugs parameters while independent <italic toggle="yes">t-</italic>test was applied on continuous variables such as age, and clinical parameters etc. P value less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><p>Two hundred individuals were enrolled in this study; 100 RA including 15 males and 85 females with a mean age of 40.13&#x000b1;14.05 years and 100 randomly selected age-matched control individuals including 44 males and 56 females under a mean age of 42.44&#x000b1;12.21. The mean disease duration of RA patients was 6.61&#x000b1;6.23 years. Overall, 45% of RA samples and 9% of control cases were found positive for EBV DNA by nested PCR with significant association (P = 0.00001). All EBV-positive RA patients were confirmed having EBV-1 genotypes (<bold><xref rid="pone.0295124.t001" ref-type="table">Table 1</xref></bold>).</p><table-wrap position="float" id="pone.0295124.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0295124.t001</object-id><label>Table 1</label><caption><title>Demographics and laboratory parameters of RA patients.</title></caption><alternatives><graphic xlink:href="pone.0295124.t001" id="pone.0295124.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" colspan="2" rowspan="1">Frequency</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex (Male/Female)</bold>
</td><td align="left" colspan="2" rowspan="1">15/85</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SPRA/SNRA</bold>
</td><td align="justify" colspan="2" rowspan="1">86/14</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RA family history (positive/ negative)</bold>
</td><td align="justify" colspan="2" rowspan="1">21/79</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Variables</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Mean (&#x000b1;Sd)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Range</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="left" rowspan="1" colspan="1">40.13 &#x000b1; 14.05</td><td align="left" rowspan="1" colspan="1">18&#x02013;83</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Disease duration (years)</bold>
</td><td align="left" rowspan="1" colspan="1">6.61 &#x000b1; 6.23</td><td align="left" rowspan="1" colspan="1">0.5&#x02013;30</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CRP (mg/L)</bold>
</td><td align="left" rowspan="1" colspan="1">8.7 &#x000b1; 6.87</td><td align="left" rowspan="1" colspan="1">0.3&#x02013;48.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>WBC (&#x000d7;10</bold>
<sup>
<bold>3</bold>
</sup>
<bold>/ uL)</bold>
</td><td align="left" rowspan="1" colspan="1">9.8 &#x000b1; 3.19</td><td align="left" rowspan="1" colspan="1">3.2&#x02013;26.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>RBC (&#x000d7;10</bold>
<sup>
<bold>6</bold>
</sup>
<bold>/ uL)</bold>
</td><td align="left" rowspan="1" colspan="1">4.6 &#x000b1; 0.81</td><td align="left" rowspan="1" colspan="1">3.2&#x02013;10</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>PLT count (&#x000d7;10</bold>
<sup>
<bold>3</bold>
</sup>
<bold>/ uL)</bold>
</td><td align="left" rowspan="1" colspan="1">398.8 &#x000b1; 143.1</td><td align="left" rowspan="1" colspan="1">118&#x02013;805</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ALT (U/L)</bold>
</td><td align="left" rowspan="1" colspan="1">24.32 &#x000b1; 12.49</td><td align="left" rowspan="1" colspan="1">3&#x02013;85</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ALP (U/L)</bold>
</td><td align="left" rowspan="1" colspan="1">108.8 &#x000b1; 51.4</td><td align="left" rowspan="1" colspan="1">29&#x02013;409</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Serum creatinine (mg/dL)</bold>
</td><td align="left" rowspan="1" colspan="1">0.69 &#x000b1; 0.20</td><td align="left" rowspan="1" colspan="1">0.24&#x02013;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Urea (mg/dL)</bold>
</td><td align="left" rowspan="1" colspan="1">28.8 &#x000b1;10.3</td><td align="left" rowspan="1" colspan="1">10&#x02013;46</td></tr></tbody></table></alternatives></table-wrap><p>EBV positivity percentage in each age group of RA is shown in <bold><xref rid="pone.0295124.g001" ref-type="fig">Fig 1</xref></bold>. The Prevalence of EBV was higher in females (82%) than in males (18%) RA patients (P = 0.481). The majority of RA patients were under the age range 21&#x02013;40 years followed by the 41&#x02013;60 years&#x02019; age group. EBV detection in the age group &#x02265;60 years was comparatively higher than in the other groups. No statistically significant association was observed between age and EBV presence (P = 0.343).</p><fig position="float" id="pone.0295124.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0295124.g001</object-id><label>Fig 1</label><caption><title>Prevalence of EBV in different age groups of RA patients.</title></caption><graphic xlink:href="pone.0295124.g001" position="float"/></fig><p>EBV positive and negative RA patients showed no significant difference concerning clinical and laboratory parameters such as CRP (P = 0.313), WBC (P = 0.249), RBC (P = 0.171), PLT (P = 0.729), ALT (P = 0.200), ALP (P = 0.067), and urea (P = 0.046) except serum creatinine (P = 0.022), shown in <xref rid="pone.0295124.t002" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="pone.0295124.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0295124.t002</object-id><label>Table 2</label><caption><title>Clinical and demographic characteristics of RA patients in correlation with EBV.</title></caption><alternatives><graphic xlink:href="pone.0295124.t002" id="pone.0295124.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Parameters</th><th align="left" rowspan="1" colspan="1">EBV positive</th><th align="left" rowspan="1" colspan="1">EBV negative</th><th align="left" rowspan="2" colspan="1">p- value</th></tr><tr><th align="left" rowspan="1" colspan="1">n = 45</th><th align="left" rowspan="1" colspan="1">n = 55</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">
<bold>Gender (female/male)</bold>
</td><td align="left" rowspan="1" colspan="1">82/18 (%)</td><td align="left" rowspan="1" colspan="1">87/13 (%)</td><td align="left" rowspan="1" colspan="1">0.481*</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="left" rowspan="1" colspan="1">41.55 &#x000b1; 14.83</td><td align="left" rowspan="1" colspan="1">38.89 &#x000b1; 13.09</td><td align="left" rowspan="1" colspan="1">0.343</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>CRP (mg/L)</bold>
</td><td align="left" rowspan="1" colspan="1">8.02 &#x000b1; 2.11</td><td align="left" rowspan="1" colspan="1">9.26 &#x000b1; 7.98</td><td align="left" rowspan="1" colspan="1">0.313</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>WBC (&#x000d7;103/ &#x003bc;L)</bold>
</td><td align="left" rowspan="1" colspan="1">10.24 &#x000b1; 3.69</td><td align="left" rowspan="1" colspan="1">9.50 &#x000b1; 2.67</td><td align="left" rowspan="1" colspan="1">0.249</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>RBC (&#x000d7;106/ &#x003bc;L)</bold>
</td><td align="left" rowspan="1" colspan="1">4.73 &#x000b1; 1.07</td><td align="left" rowspan="1" colspan="1">4.51 &#x000b1; 0.46</td><td align="left" rowspan="1" colspan="1">0.171</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>PLT count (&#x000d7;103/ &#x003bc;L)</bold>
</td><td align="left" rowspan="1" colspan="1">404.37 &#x000b1; 146.92</td><td align="left" rowspan="1" colspan="1">394.38 &#x000b1; 139.85</td><td align="left" rowspan="1" colspan="1">0.729</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>ALT (U/L)</bold>
</td><td align="left" rowspan="1" colspan="1">26.08 &#x000b1; 12.04</td><td align="left" rowspan="1" colspan="1">22.87 &#x000b1; 12.66</td><td align="left" rowspan="1" colspan="1">0.200</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>ALP (U/L)</bold>
</td><td align="left" rowspan="1" colspan="1">98.46 &#x000b1; 29.94</td><td align="left" rowspan="1" colspan="1">117.30 &#x000b1; 62.58</td><td align="left" rowspan="1" colspan="1">0.067</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Serum creatinine (mg/dL)</bold>
</td><td align="left" rowspan="1" colspan="1">0.64 &#x000b1; 0.17</td><td align="left" rowspan="1" colspan="1">0.73 &#x000b1; 0.21</td><td align="left" rowspan="1" colspan="1">0.022</td></tr><tr><td align="justify" rowspan="1" colspan="1">
<bold>Urea (mg/dL)</bold>
</td><td align="left" rowspan="1" colspan="1">26.55 &#x000b1; 10.58</td><td align="left" rowspan="1" colspan="1">30.61 &#x000b1; 9.56</td><td align="left" rowspan="1" colspan="1">0.046</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>*Chi square test</p></fn></table-wrap-foot></table-wrap><p>Patients were further characterized based on the drug of choice; the number of patients using Disease-modifying anti-rheumatic drugs (DMARDs) was comparatively higher than patients using biologics and steroid-DMARDs category. EBV prevalence was found higher in biologics-taking patients (60%) compared to DMARDs (43%) and steroid-DMARDs category (42.3%) (P = 0.599). Among 100 RA samples, 21 had a positive family history of RA within which 81% were positive for EBV showing a significant (P = 0.0001) correlation with RA (<bold><xref rid="pone.0295124.t003" ref-type="table">Table 3</xref></bold>). Out of 86 SPRA patients, 43% were positive for EBV. Moreover, a significant association of the RA major subset (SPRA and SNRA) was found with a family history of RA in EBV-positive RA individuals (P = 0.017) (<bold><xref rid="pone.0295124.t004" ref-type="table">Table 4</xref></bold>).</p><table-wrap position="float" id="pone.0295124.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0295124.t003</object-id><label>Table 3</label><caption><title>Association of EBV with RA immunosuppressive type of treatment, family history and type of RA (SPRA and SNRA).</title></caption><alternatives><graphic xlink:href="pone.0295124.t003" id="pone.0295124.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Immunosuppressive drug categories (n)</th><th align="left" rowspan="1" colspan="1">EBV positive</th><th align="left" rowspan="1" colspan="1">EBV negative</th><th align="left" rowspan="2" colspan="1">p- value</th></tr><tr><th align="left" rowspan="1" colspan="1">n(%)</th><th align="left" rowspan="1" colspan="1">n(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DMARDs (64)</td><td align="left" rowspan="1" colspan="1">28 (43.8)</td><td align="left" rowspan="1" colspan="1">36 (56.2)</td><td align="left" rowspan="3" colspan="1">0.599</td></tr><tr><td align="left" rowspan="1" colspan="1">DMARDs-steroids (26)</td><td align="left" rowspan="1" colspan="1">11 (42.3)</td><td align="left" rowspan="1" colspan="1">15 (57.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Biologics (10)</td><td align="left" rowspan="1" colspan="1">6 (60)</td><td align="left" rowspan="1" colspan="1">4 (40)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Family history (n)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="3" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive (21)</td><td align="left" rowspan="1" colspan="1">17 (81)</td><td align="left" rowspan="1" colspan="1">4 (19)</td></tr><tr><td align="left" rowspan="1" colspan="1">Negative (79)</td><td align="left" rowspan="1" colspan="1">28 (35)</td><td align="left" rowspan="1" colspan="1">51 (64)</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0295124.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0295124.t004</object-id><label>Table 4</label><caption><title>Association of EBV, family history and type of RA (SPRA and SNRA).</title></caption><alternatives><graphic xlink:href="pone.0295124.t004" id="pone.0295124.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="2">Parameters</th><th align="left" colspan="2" rowspan="1">Presence of autoantibodies (RA and Anti- CCP)</th><th align="left" rowspan="2" colspan="1">Total</th><th align="left" rowspan="2" colspan="1">p- value</th></tr><tr><th align="left" rowspan="1" colspan="1">SPRA (n = 86)</th><th align="left" rowspan="1" colspan="1">SNRA (n = 14)</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">
<bold>EBV Positive</bold>
</td><td align="left" rowspan="2" colspan="1">Positive RA family history</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="6" colspan="1">
<bold>0.017</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">64.7%</td><td align="left" rowspan="1" colspan="1">35.3%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Negative RA family history</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">92.9%</td><td align="left" rowspan="1" colspan="1">7.1%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="2">Total</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">82.2%</td><td align="left" rowspan="1" colspan="1">17.8%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">
<bold>EBV Negative</bold>
</td><td align="left" rowspan="2" colspan="1">Positive RA family history</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="6" colspan="1">0.348</td></tr><tr><td align="left" rowspan="1" colspan="1">75.0%</td><td align="left" rowspan="1" colspan="1">25.0%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Negative RA family history</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">90.2%</td><td align="left" rowspan="1" colspan="1">9.8%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" rowspan="2">Total</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">89.1%</td><td align="left" rowspan="1" colspan="1">10.9%</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec sec-type="conclusions" id="sec013"><title>Discussion and conclusion</title><p>RA patients showed strong susceptibility to a variety of diseases that either worsen their overall complications or contribute to their pathogenesis causing arthralgia and arthritis [<xref rid="pone.0295124.ref018" ref-type="bibr">18</xref>]. This may lead to complications added by poor health and hygienic conditions contributing to various viruses causing such diseases [<xref rid="pone.0295124.ref019" ref-type="bibr">19</xref>]. The viruses associated with RA may spread through unscreened blood transfusion, saliva, sharing of drinks/eating utensils, and other personal use items [<xref rid="pone.0295124.ref020" ref-type="bibr">20</xref>]. In the current study, the prevalence of EBV was 45% in RA and 9% in control individuals. Likewise, a 79% EBV prevalence rate was detected in the Sardinian RA population conducted by Erre et al. [<xref rid="pone.0295124.ref006" ref-type="bibr">6</xref>]. In line with our findings, other researchers found 40% [<xref rid="pone.0295124.ref021" ref-type="bibr">21</xref>] and 29.2% [<xref rid="pone.0295124.ref022" ref-type="bibr">22</xref>] EBV prevalence rate in the RA population. The variation in findings of mentioned studies is partly attributable to the differences in the prevalence rate of EBV and RA worldwide.</p><p>RA patients&#x02019; samples were further analyzed for EBV genotype specification. According to our findings, only the type 1 genotype of EBV was prevalent in RA patients. A study performed in Pakistan on lymphoma patients detected both genotypes, with type 1 being most prevalent (90%) than type 2 (9%) [<xref rid="pone.0295124.ref012" ref-type="bibr">12</xref>]. Similarly, another study [<xref rid="pone.0295124.ref023" ref-type="bibr">23</xref>] observed 60% of type 1 and 26% of type 2 EBV genotypes in transgender sex workers in Pakistan. Likewise, Salahuddin et al. [<xref rid="pone.0295124.ref024" ref-type="bibr">24</xref>] also reported a high prevalence of the type- 1 (40%) genotype compared to type- 2 (15%) in HIV-infected Pakistani transsexual individuals. To our knowledge, this is the first time to perform detection of the EBV genotype in RA patients. One of the possible explanations for the 100%, type 1 genotype in our study is due to the high prevalence of only type 1 genotype in our area.</p><p>In this study, no significant relationship has been observed between RA demographic, clinical, and laboratory parameters such as gender, age, RA family history, disease duration, CRP, WBC, RBC, PLT, ALT, ALP, Urea, Type of immunosuppressive therapy, family history and type of RA (SPRA and SPNA) with EBV presence except serum creatinine. The study carried out by Costenbader and Karlson [<xref rid="pone.0295124.ref025" ref-type="bibr">25</xref>] also demonstrated that the presence of EBV is not influenced by the presence or absence of RF, age, duration of RA, disease activity, or RA treatment. In agreement, Hamid [<xref rid="pone.0295124.ref026" ref-type="bibr">26</xref>] did not report any correlation between the seroprevalence of EBV and some RA parameters i.e., CRP, ESR, and WBCs count in blood, which might infer that EBV plays a role in the onset of RA, but have no link with further steps in the pathogenesis of RA.</p><p>Therapies for the treatment of RA are very effective but can initiate multiple mechanisms affecting immune surveillance of latently EBV-infected cells initiating continuous viral reactivation and persistent immune stimulation mostly in long-term treatment [<xref rid="pone.0295124.ref027" ref-type="bibr">27</xref>]. Our study showed no significant correlation of drug category with the presence of EBV while biologics using RA patients tended to have comparatively high EBV seropositivity but this did not reach significance. Correspondingly, a study with similar findings compared the seropositivity of EBV in patients taking immunosuppressive drugs such as steroids and DMARDs observing no significant association [<xref rid="pone.0295124.ref028" ref-type="bibr">28</xref>]. In accordance, other research studies [<xref rid="pone.0295124.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0295124.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0295124.ref030" ref-type="bibr">30</xref>] also didn&#x02019;t show any significant positive correlation between EBV and RA medication including biologics and DMARDs.</p><p>Moreover, this work indicates the significant correlation of EBV presence with family history and major subtypes of RA (SPRA and SNRA). However, there was no supporting evidence found from other studies regarding the link of EBV with RA family history and its combined association with RA subtypes. This finding could be explained by the possibility that the inheritance of susceptible genes involved in the onset of RA may contribute to molecular mimicry between EBV and self-proteins leading to a loss of immune tolerance in the predisposed host [<xref rid="pone.0295124.ref031" ref-type="bibr">31</xref>].</p><p>In summary, this study showed that RA patients have a high prevalence of EBV and especially the type 1 genotype thus suggesting EBV&#x02019;s significant role as a trigger in the onset or exacerbation of RA. Additional efforts are required for genetic analysis of RA-associated genes in patients carrying EBV as an agent for acquiring RA. This research further suggests the genetic analysis of EBV i.e. different strains and variant investigation present in our area involved in RA as well as the study on preventive strategies for interrupting EBV transmissions such as vaccine and other antiviral drug development that would be effective for halting RA.</p></sec><sec id="sec014" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0295124.s001" position="float" content-type="local-data"><label>S1 Fig</label><caption><p>(TIF)</p></caption><media xlink:href="pone.0295124.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0295124.s002" position="float" content-type="local-data"><label>S1 Raw image</label><caption><p>(PDF)</p></caption><media xlink:href="pone.0295124.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0295124.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>Q</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Xu</surname><given-names>D</given-names></name>, <name><surname>Nossent</surname><given-names>J</given-names></name>, <name><surname>Pavlos</surname><given-names>NJ</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>. <article-title>Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies</article-title>. <source>Bone research</source>. <year>2018</year>;<volume>6</volume>(<issue>1</issue>):<fpage>15</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41413-018-0016-9</pub-id>
<pub-id pub-id-type="pmid">29736302</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Cho</surname><given-names>S-K</given-names></name>, <name><surname>Choi</surname><given-names>S</given-names></name>, <name><surname>Im</surname><given-names>SG</given-names></name>, <name><surname>Jung</surname><given-names>S-Y</given-names></name>, <name><surname>Jang</surname><given-names>EJ</given-names></name>, <etal>et al</etal>. <article-title>Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis.</article-title>
<source>Ther Adv Musculoskelet Dis</source>. <year>2021</year>;<volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>110</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1759720X211024830</pub-id>
<pub-id pub-id-type="pmid">34262621</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Balandraud</surname><given-names>N</given-names></name>, <name><surname>Roudier</surname><given-names>J</given-names></name>, <name><surname>Roudier</surname><given-names>C</given-names></name>. <article-title>Epstein&#x02013;Barr virus and rheumatoid arthritis</article-title>. <source>Autoimmunity reviews</source>. <year>2004</year>;<volume>3</volume>(<issue>5</issue>):<fpage>362</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.autrev.2004.02.002</pub-id>
<pub-id pub-id-type="pmid">15288002</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>H-J</given-names></name>, <name><surname>Ko</surname><given-names>YH</given-names></name>, <name><surname>Kim</surname><given-names>JE</given-names></name>, <name><surname>Lee</surname><given-names>S-S</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <name><surname>Park</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Epstein-Barr virus&#x02013;associated lymphoproliferative disorders: review and update on 2016 WHO classification.</article-title>
<source>Journa of pathology and translational medicine.</source>
<year>2017</year>;<volume>51</volume>(<issue>4</issue>):<fpage>352</fpage>.</mixed-citation></ref><ref id="pone.0295124.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Smatti</surname><given-names>MK</given-names></name>, <name><surname>Yassine</surname><given-names>HM</given-names></name>, <name><surname>AbuOdeh</surname><given-names>R</given-names></name>, <name><surname>AlMarawani</surname><given-names>A</given-names></name>, <name><surname>Taleb</surname><given-names>SA</given-names></name>, <name><surname>Althani</surname><given-names>AA</given-names></name>, <etal>et al</etal>. <article-title>Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar.</article-title>
<source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e0189033</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0189033</pub-id>
<pub-id pub-id-type="pmid">29228016</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Erre</surname><given-names>GL</given-names></name>, <name><surname>Mameli</surname><given-names>G</given-names></name>, <name><surname>Cossu</surname><given-names>D</given-names></name>, <name><surname>Muzzeddu</surname><given-names>B</given-names></name>, <name><surname>Piras</surname><given-names>C</given-names></name>, <name><surname>Paccagnini</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Increased Epstein-Barr virus DNA load and antibodies against EBNA1 and EA in sardinian patients with rheumatoid arthritis</article-title>. <source>Viral immunology</source>. <year>2015</year>;<volume>28</volume>(<issue>7</issue>):<fpage>385</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1089/vim.2015.0035</pub-id>
<pub-id pub-id-type="pmid">26083265</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Balandraud</surname><given-names>N</given-names></name>, <name><surname>Texier</surname><given-names>G</given-names></name>, <name><surname>Massy</surname><given-names>E</given-names></name>, <name><surname>Muis-Pistor</surname><given-names>O</given-names></name>, <name><surname>Martin</surname><given-names>M</given-names></name>, <name><surname>Auger</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis-A three years retrospective study.</article-title>
<source>PLoS One.</source>
<year>2017</year>;<volume>12</volume>(<issue>2</issue>):<fpage>e0171623</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0171623</pub-id>
<pub-id pub-id-type="pmid">28199343</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Masuoka</surname><given-names>S</given-names></name>, <name><surname>Kusunoki</surname><given-names>N</given-names></name>, <name><surname>Takamatsu</surname><given-names>R</given-names></name>, <name><surname>Takahashi</surname><given-names>H</given-names></name>, <name><surname>Tsuchiya</surname><given-names>K</given-names></name>, <name><surname>Kawai</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis.</article-title>
<source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>12</issue>):<fpage>e0208957</fpage>.<pub-id pub-id-type="pmid">30533036</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Svendsen</surname><given-names>AJ</given-names></name>, <name><surname>Westergaard</surname><given-names>MCW</given-names></name>, <name><surname>Draborg</surname><given-names>AH</given-names></name>, <name><surname>Holst</surname><given-names>R</given-names></name>, <name><surname>Kyvik</surname><given-names>KO</given-names></name>, <name><surname>Jakobsen</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Altered antibody response to epstein-barr virus in patients with rheumatoid arthritis and healthy subjects predisposed to the disease. A twin study</article-title>. <source>Frontiers in Immunology</source>. <year>2021</year>;<volume>12</volume>:<fpage>650713</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2021.650713</pub-id>
<pub-id pub-id-type="pmid">33777048</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Perez</surname><given-names>G</given-names></name>, <name><surname>Svetaz</surname><given-names>MJ</given-names></name>, <name><surname>Urli</surname><given-names>L</given-names></name>, <name><surname>Volpintesta</surname><given-names>R</given-names></name>, <name><surname>Taborda</surname><given-names>MA</given-names></name>, <name><surname>Gardiol</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Evidence of association between epstein barr virus serum antibodies with HAs and RI as biomarkers of active rheumatoid arthritis.</article-title>
<source>Current Biomarkers (Formerly: Recent Patents on Biomarkers).</source>
<year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Masdar</surname><given-names>H.</given-names></name>
<article-title>The link of Epstein Barr virus infection and rheumatoid arthritis immunopathogenesis.</article-title>
<source>Jurnal Ilmu Kedokteran (Journal of Medical Science).</source>
<year>2017</year>;<volume>4</volume>(<issue>2</issue>):<fpage>79</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Salahuddin</surname><given-names>S</given-names></name>, <name><surname>Khan</surname><given-names>J</given-names></name>, <name><surname>Azhar</surname><given-names>J</given-names></name>, <name><surname>Whitehurst</surname><given-names>CB</given-names></name>, <name><surname>Qadri</surname><given-names>I</given-names></name>, <name><surname>Shackelford</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of Epstein&#x02013;Barr virus genotypes in Pakistani lymphoma patients. Asian Pacific journal of cancer prevention</article-title>: <source>APJCP</source>. <year>2018</year>;<volume>19</volume>(<issue>11</issue>):<fpage>3153</fpage>.<pub-id pub-id-type="pmid">30486603</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ziaullah</surname><given-names>S</given-names></name>, <name><surname>Ahmad</surname><given-names>S</given-names></name>, <name><surname>Khan</surname><given-names>MM</given-names></name>, <name><surname>Alam</surname><given-names>S</given-names></name>, <name><surname>Nasir</surname><given-names>S</given-names></name>, <name><surname>Sharif</surname><given-names>N</given-names></name>. <article-title>Epstein Barr Virus LMP-1 Positivity in Hodgkin Lymphoma Subtypes, in Khyber Pakhtunkhwa Province of Pakistan.</article-title>
<source>Gomal Journal of Medical Sciences</source>. <year>2017</year>;<volume>15</volume>(<issue>1</issue>).</mixed-citation></ref><ref id="pone.0295124.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Azhar</surname><given-names>M</given-names></name>, <name><surname>ud Din</surname><given-names>H</given-names></name>, <name><surname>Muhammad</surname><given-names>I</given-names></name>, <name><surname>Hashmi</surname><given-names>SN</given-names></name>, <name><surname>Akhtar</surname><given-names>F</given-names></name>. <article-title>Frequency of epstein-barr virus in classical hodgkin Lymphoma</article-title>. <source>Journal of Ayub Medical College Abbottabad</source>. <year>2016</year>;<volume>28</volume>(<issue>2</issue>):<fpage>271</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">28718560</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Naqvi</surname><given-names>AA</given-names></name>, <name><surname>Hassali</surname><given-names>MA</given-names></name>, <name><surname>Aftab</surname><given-names>MT</given-names></name>. <article-title>Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients: A systematic review and meta-analysis</article-title>. <source>JPMA The Journal of the Pakistan Medical Association</source>. <year>2019</year>;<volume>69</volume>(<issue>3</issue>):<fpage>389</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="pmid">30890833</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Aletaha</surname><given-names>D</given-names></name>, <name><surname>Neogi</surname><given-names>T</given-names></name>, <name><surname>Silman</surname><given-names>AJ</given-names></name>, <name><surname>Funovits</surname><given-names>J</given-names></name>, <name><surname>Felson</surname><given-names>DT</given-names></name>, <name><surname>Bingham</surname><given-names>CO</given-names><suffix>III</suffix></name>, <etal>et al</etal>. <article-title>2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title>. <source>Arthritis &#x00026; rheumatism.</source>
<year>2010</year>;<volume>62</volume>(<issue>9</issue>):<fpage>2569</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">20872595</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Sharifpour</surname><given-names>C</given-names></name>, <name><surname>Makvandi</surname><given-names>M</given-names></name>, <name><surname>Samarbafzadeh</surname><given-names>A</given-names></name>, <name><surname>Talaei-Zadeh</surname><given-names>A</given-names></name>, <name><surname>Ranjbari</surname><given-names>N</given-names></name>, <name><surname>Nisi</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Frequency of Epstein&#x02013;Barr virus DNA in formalin-fixed paraffin-embedded tissue of patients with ductal breast carcinoma.</article-title>
<source>Asian Pacific Journal of Cancer Prevention: APJCP.</source>
<year>2019</year>;<volume>20</volume>(<issue>3</issue>):<fpage>687</fpage>.<pub-id pub-id-type="pmid">30909665</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Jeong</surname><given-names>H</given-names></name>, <name><surname>Baek</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>SW</given-names></name>, <name><surname>Eun</surname><given-names>YH</given-names></name>, <name><surname>Kim</surname><given-names>IY</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Comorbidities of rheumatoid arthritis: results from the Korean National Health and Nutrition Examination Survey.</article-title>
<source>PLoS One.</source>
<year>2017</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e0176260</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0176260</pub-id>
<pub-id pub-id-type="pmid">28423031</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Jefferson</surname><given-names>T</given-names></name>, <name><surname>Foxlee</surname><given-names>R</given-names></name>, <name><surname>Del Mar</surname><given-names>C</given-names></name>, <name><surname>Dooley</surname><given-names>L</given-names></name>, <name><surname>Ferroni</surname><given-names>E</given-names></name>, <name><surname>Hewak</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review</article-title>. <source>Bmj</source>. <year>2008</year>;<volume>336</volume>(<issue>7635</issue>):<fpage>77</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.39393.510347.BE</pub-id>
<pub-id pub-id-type="pmid">18042961</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Podzimek</surname><given-names>S</given-names></name>, <name><surname>Vondrackova</surname><given-names>L</given-names></name>, <name><surname>Duskova</surname><given-names>J</given-names></name>, <name><surname>Janatova</surname><given-names>T</given-names></name>, <name><surname>Broukal</surname><given-names>Z</given-names></name>. <article-title>Salivary markers for periodontal and general diseases</article-title>. <source>Disease markers</source>. <year>2016</year>; <volume>2016</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2016/9179632</pub-id>
<pub-id pub-id-type="pmid">27143814</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bassyouni</surname><given-names>RH</given-names></name>, <name><surname>Dwedar</surname><given-names>RA</given-names></name>, <name><surname>Ezzat</surname><given-names>EM</given-names></name>, <name><surname>Marzaban</surname><given-names>RN</given-names></name>, <name><surname>Nassr</surname><given-names>MH</given-names></name>, <name><surname>Rashid</surname><given-names>L</given-names></name>. <article-title>Elevated Cytomegalovirus and Epstein-Barr virus burden in rheumatoid arthritis: A true pathogenic role or just a coincidence.</article-title>
<source>The Egyptian Rheumatologist.</source>
<year>2019</year>;<volume>41</volume>(<issue>4</issue>):<fpage>255</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Sorgato</surname><given-names>CC</given-names></name>, <name><surname>Lins&#x02010;e&#x02010;Silva</surname><given-names>M</given-names></name>, <name><surname>Le&#x000e3;o</surname><given-names>JC</given-names></name>, <name><surname>Vasconcelos</surname><given-names>LR</given-names></name>, <name><surname>Rom&#x000e3;o</surname><given-names>TP</given-names></name>, <name><surname>Duarte</surname><given-names>AL</given-names></name>, <etal>et al</etal>. <article-title>EBV and CMV viral load in rheumatoid arthritis and their role in associated Sj&#x000f6;gren&#x02019;s syndrome. Journal of Oral Pathology &#x00026;</article-title>
<source>Medicine</source>. <year>2020</year>;<volume>49</volume>(<issue>7</issue>):<fpage>693</fpage>&#x02013;<lpage>700</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref023"><label>23</label><mixed-citation publication-type="book"><name><surname>Din</surname><given-names>SS</given-names></name>, editor <source>Frequency of Epstein&#x02013;Barr Virus Genotypes in Pakistani Trangender SexWorkers. Open forum infectious diseases</source>; <year>2017</year>: <publisher-name>Oxford University Press</publisher-name>.</mixed-citation></ref><ref id="pone.0295124.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Salahuddin</surname><given-names>S</given-names></name>, <name><surname>Azhar</surname><given-names>J</given-names></name>, <name><surname>Akhtar</surname><given-names>H</given-names></name>, <name><surname>Khan</surname><given-names>J</given-names></name>, <name><surname>Muhammad</surname><given-names>N</given-names></name>. <article-title>Epstein-Barr virus epidemiology in HIV infected transsexuals</article-title>. <source>JPMA The Journal of the Pakistan Medical Association</source>. <year>2021</year>;<volume>71</volume>(<issue>8</issue>):<fpage>1984</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.47391/JPMA.02-339</pub-id>
<pub-id pub-id-type="pmid">34418015</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Costenbader</surname><given-names>KH</given-names></name>, <name><surname>Karlson</surname><given-names>EW</given-names></name>. <article-title>Epstein&#x02013;Barr virus and rheumatoid arthritis: is there a link?</article-title>
<source>Arthritis research &#x00026; therapy.</source>
<year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/ar1893</pub-id>
<pub-id pub-id-type="pmid">16542469</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Hamid</surname><given-names>ZA</given-names></name>. <article-title>The Impact of Hepatitis B Virus and Epstein-Barr Virus in Pathogenesis of Rheumatoid Arthritis.</article-title>
<source>Biomedical and Pharmacology Journal</source>. <year>2017</year>;<volume>10</volume>(<issue>3</issue>):<fpage>1495</fpage>&#x02013;<lpage>501</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>JP</given-names></name>, <name><surname>Gosselin</surname><given-names>J</given-names></name>. <article-title>Does Epstein-Barr Virus Infection Contribute to Disease Flares in Rheumatoid Arthritis?</article-title>
<source>Journal of Arthritis</source>. <year>2016</year>:<fpage>1</fpage>&#x02013;<lpage>2</lpage>.</mixed-citation></ref><ref id="pone.0295124.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Westergaard</surname><given-names>MW</given-names></name>, <name><surname>Draborg</surname><given-names>AH</given-names></name>, <name><surname>Troelsen</surname><given-names>L</given-names></name>, <name><surname>Jacobsen</surname><given-names>S</given-names></name>, <name><surname>Houen</surname><given-names>G</given-names></name>. <article-title>Isotypes of Epstein-Barr virus antibodies in rheumatoid arthritis: association with rheumatoid factors and citrulline-dependent antibodies.</article-title>
<source>BioMed research international.</source>
<year>2015</year>;<volume>2015</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2015/472174</pub-id>
<pub-id pub-id-type="pmid">26000294</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Miceli-Richard</surname><given-names>C</given-names></name>, <name><surname>Gestermann</surname><given-names>N</given-names></name>, <name><surname>Amiel</surname><given-names>C</given-names></name>, <name><surname>Sellam</surname><given-names>J</given-names></name>, <name><surname>Ittah</surname><given-names>M</given-names></name>, <name><surname>Pavy</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.</article-title>
<source>Arthritis Research &#x00026; Therapy.</source>
<year>2009</year>;<volume>11</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/ar2708</pub-id>
<pub-id pub-id-type="pmid">19470150</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Williamson</surname><given-names>L</given-names></name>, <name><surname>Cai</surname><given-names>K</given-names></name>, <name><surname>Wong</surname><given-names>P</given-names></name>, <name><surname>Sturgess</surname><given-names>A</given-names></name>, <name><surname>Taper</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Epstein&#x02013;Barr virus&#x02010;related lymphoma in rheumatoid arthritis: implications for long&#x02010;term usage of immunosuppressive drugs and review of the literature</article-title>. <source>Internal Medicine Journal</source>. <year>2022</year>;<volume>52</volume>(<issue>10</issue>):<fpage>1717</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/imj.15390</pub-id>
<pub-id pub-id-type="pmid">34028145</pub-id>
</mixed-citation></ref><ref id="pone.0295124.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Bo</surname><given-names>M</given-names></name>, <name><surname>Niegowska</surname><given-names>M</given-names></name>, <name><surname>Erre</surname><given-names>GL</given-names></name>, <name><surname>Piras</surname><given-names>M</given-names></name>, <name><surname>Longu</surname><given-names>MG</given-names></name>, <name><surname>Manchia</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Rheumatoid arthritis patient antibodies highly recognize IL-2 in the immune response pathway involving IRF5 and EBV antigens.</article-title>
<source>Scientific reports.</source>
<year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1789</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-018-19957-z</pub-id>
<pub-id pub-id-type="pmid">29379122</pub-id>
</mixed-citation></ref></ref-list></back></article>
